Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$19.06

0.54 (2.92%)

, JNJ

Johnson & Johnson

$139.91

2.035 (1.48%)

07:33
04/24/19
04/24
07:33
04/24/19
07:33

Arrowhead begins triple combination cohort in chronic HBV patients

Arrowhead Pharmaceuticals (ARWR) announced that it has begun dosing in a new triple combination cohort that includes JNJ-3989 and additional undisclosed agents selected by Janssen Pharmaceuticals (JNJ) in its ongoing Phase 1/2 study in patients with chronic hepatitis B virus. In connection with the start of this new cohort, Arrowhead has earned a $25M milestone payment from Janssen Pharmaceuticals. AROHBV1001 is a Phase 1/2 clinical study evaluating the safety, tolerability, and pharmacokinetic effects of single-ascending doses of ARO-HBV in healthy adult volunteers, as well as the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses of ARO-HBV in patients with chronic HBV. Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialize ARO-HBV. Under the initial terms of the HBV license agreement, Arrowhead was eligible to receive a $50M milestone payment linked to a Phase 2 study. Arrowhead and Janssen subsequently amended the HBV license agreement to accelerate the payment of $25M of the $50M Phase 2 milestone with the initiation of cohort 12 of the AROHBV1001 trial. Arrowhead is eligible to receive the remaining $25M upon the initiation of a Phase 2 study by Janssen.

ARWR

Arrowhead

$19.06

0.54 (2.92%)

JNJ

Johnson & Johnson

$139.91

2.035 (1.48%)

  • 25

    Apr

  • 16

    Jul

ARWR Arrowhead
$19.06

0.54 (2.92%)

10/17/18
PIPR
10/17/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead 25% pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Arrowhead Pharmaceuticals with a $25 price target following yesterday's R&D day. The analyst is a buyer on recent weakness with the stock down 25% since announcing the Janssen deal earlier this month. Arrowhead now trades at a market capitalization of $1.27B with pro forma cash of $328M to advance its wholly-owned RNAi pipeline, Tenthoff tells investors in a research note. He points out the company will give an oral presentation on ARO-AAT including Phase I safety and serum Alpha-1 Antitrypsin levels in healthy volunteers in a late-breaker at the annual American Association for the study of Liver Diseases meeting on November 12.
11/12/18
PIPR
11/12/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead's new data validate TRiM pipeline, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes new data presented by Arrowhead (ARWR) at the AASLD meeting on ARO-AAT and ARO-HBV validate the company's proprietary TRiM platform. He expects a potentially registrational Phase 2/3 trial for ARO-AAT to start in the first quarter of 2019 and noted that partner Janssen (JNJ) intends to begin Phase 2 studies of ARO-HBV in the first half of next year. Tenthoff keeps an Overweight rating and $25 price target on Arrowhead shares.
01/07/19
PIPR
01/07/19
NO CHANGE
PIPR
Piper Jaffray optimistic on Arrowhead as multiple studies commencing
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $25 price target on Arrowhead Pharmaceuticals after the company announced it dosed the first patient in Phase I ARO-ANG3 study and will commence Phase I dosing of ARO-APOC3 upon CTA approval. The analyst also sees at least two additional TRiM RNAi candidates entering the clinic in 2019, including ARO-ENaC and ARO-HIF2. Most important, Arrowhead will initiate a potentially registrational Phase II/III study for ARO-AAT in Q1 of 2019.
04/16/19
PIPR
04/16/19
NO CHANGE
Target $33
PIPR
Overweight
Arrowhead price target raised to $33 from $25 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $33 from $25 after the company received FDA clearance to start a Phase II/III trial of wholly-owned ARO-AAT in Alpha-1 antitrypsin deficiency. The analyst increased his value for ARO-AAT and reiterates an Overweight rating on Arrowhead shares.
JNJ Johnson & Johnson
$139.91

2.035 (1.48%)

04/08/19
PIPR
04/08/19
NO CHANGE
Target $20
PIPR
Overweight
Immunomedics deal with J&J indicates sacituzumab re-filing, says Piper Jaffray
Immunomedics (IMMU) this morning announced that it has entered into an agreement with Johnson & Johnson (JNJ) to provide detailing services to J&J for erdafitinib in the U.S. through Q1 of 2020, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes the deal will provide incremental revenue to Immunomedics while allowing the company to keep its sacituzumab-trained sales team on board while offsetting some of the costs. Further, the Q1 of 2020 termination suggests a potential timeline for a sacituzumab re-filing and approval, says Catanzaro, who notes Immunomedics has not yet provided guidance. The analyst remains comfortable with his mid-2020 approval timing for sacituzumab and keeps an Overweight rating on Immunomedics with a $20 price target.
04/09/19
NEED
04/09/19
UPGRADE
Target $3
NEED
Buy
Geron upgraded to Buy from Hold at Needham
Needham analyst Chad Messer upgraded Geron (GERN) to Buy with a price target of $3, saying the return of development rights for imetelstat in September by Janssen (JNJ) has created a "buying opportunity". The analyst cites the program's subsequent readouts from Phase II IMbark and IMerge studies in myelofibrosis and myelodysplastic syndrome, which he states has "established efficacy in both patient populations." Messer further contends that big pharma passing on imetelstat does not reflect a fundamental issue with the drug itself.
04/09/19
PIPR
04/09/19
NO CHANGE
Target $32
PIPR
Neutral
Alkermes' ALPINE data an incremental positive, says Piper Jaffray
After Alkermes (ALKS) reported this morning that its ALPINE trial met its primary endpoint and that Aristada showed similar efficacy to the current market leader, Invega Sustenna, at all time points assessed, Piper Jaffray analyst Danielle Brill said she views the data as an incremental positive. However, she thinks it will be challenging to capture share from Johnson & Johnson (JNJ), telling investors that she is "not sure these data will be enough to move the needle." Brill maintains a Neutral rating on Alkermes.
04/17/19
SPHN
04/17/19
NO CHANGE
SPHN
Issues facing healthcare sector now 'modest' compared to 2008-10, says Stephens
Stephens analyst Scott Fidel noted that the managed care group has sharply underperformed the S&P 500 over the last month amid "political rhetoric" around point-of-sale drug rebates and Medicare for all policy proposals, though he believes the issues facing the sector right now "seem modest in comparison" to the "dark days of 2008-2010." While recent Medicare for all proposals have rattled investors, "they will face enormous uphill battles," Fidel tells investors. Hospital stocks have outperformed MCOs year-to-date, but the group declined about 9% yesterday and underperformed the MCO group, which Fidel attributes to acknowledgement by industry bellwether UnitedHealth (UNH) of the significant disruptive nature of Medicare for all, which may have sparked additional fears, as well as one less calendar day being called out by UnitedHealth as benefiting Q1 MLRs and Johnson & Johnson's (JNJ) earnings call commentary on declining sequential hospital admissions from Q4. Publicly traded companies in the hospital space include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS). Publicly traded companies in the managed care space include Anthem (ANTM), CVS Health (CVS), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).

TODAY'S FREE FLY STORIES

14:45
06/19/19
06/19
14:45
06/19/19
14:45
General news
Fed Chair Powell opened his presser noting "significant changes" »

Fed Chair Powell opened…

SPY

SPDR S&P 500 ETF Trust

$292.63

0.3 (0.10%)

, SPX

S&P 500

$0.00

(0.00%)

14:44
06/19/19
06/19
14:44
06/19/19
14:44
General news
Powell: Trade 'important driver of sentiment,' but Fed not focused on one thing »

Asked if a trade deal…

SPY

SPDR S&P 500 ETF Trust

$292.63

0.3 (0.10%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.64

0.31 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

14:43
06/19/19
06/19
14:43
06/19/19
14:43
General news
Powell says 'law is clear I have a 4-year term,' 'fully intend to serve it' »

Asked how he would react…

SPY

SPDR S&P 500 ETF Trust

$292.64

0.31 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:42
06/19/19
06/19
14:42
06/19/19
14:42
Conference/Events
Stephens retail/broadlines analyst to hold a luncheon meeting »

Retail/Broadlines Analyst…

DIS

Disney

$140.09

0.88 (0.63%)

14:41
06/19/19
06/19
14:41
06/19/19
14:41
Periodicals
More layoffs from Disney and 20th Century Fox film divisions, Variety reports »

Matt Donelly and Brent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

SPY

SPDR S&P 500 ETF Trust

$292.48

0.15 (0.05%)

, SPX

S&P 500

$0.00

(0.00%)

14:40
06/19/19
06/19
14:40
06/19/19
14:40
General news
Powell says will be monitoring 'cross-currents,' but would 'like to see more' »

"Many" on the…

SPY

SPDR S&P 500 ETF Trust

$292.48

0.15 (0.05%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:40
06/19/19
06/19
14:40
06/19/19
14:40
Conference/Events
Stephens telecom, media & tech analyst to hold a luncheon »

Analysts hold a…

AAPL

Apple

$198.16

-0.36 (-0.18%)

, GS

Goldman Sachs

$195.66

0.68 (0.35%)

14:38
06/19/19
06/19
14:38
06/19/19
14:38
Periodicals
Apple expanding Goldman Sachs card test, Bloomberg reports »

Apple (AAPL) has launched…

AAPL

Apple

$198.16

-0.36 (-0.18%)

GS

Goldman Sachs

$195.66

0.68 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 09

    Jul

  • 16

    Jul

RHHBY

Roche

$0.00

(0.00%)

14:38
06/19/19
06/19
14:38
06/19/19
14:38
Conference/Events
Wolfe Research pharma analyst to hold an analyst/industry conference call »

Global Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 27

    Jun

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 02

    Sep

  • 04

    Nov

SPY

SPDR S&P 500 ETF Trust

$292.77

0.44 (0.15%)

, SPX

S&P 500

$0.00

(0.00%)

14:37
06/19/19
06/19
14:37
06/19/19
14:37
General news
Powell says must rely on 'imperfect' inflation expectation proxies »

Fed Chair Powell said…

SPY

SPDR S&P 500 ETF Trust

$292.77

0.44 (0.15%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$71.04

-0.13 (-0.18%)

, YELP

Yelp

$32.80

-0.13 (-0.39%)

14:36
06/19/19
06/19
14:36
06/19/19
14:36
Conference/Events
Wedbush SMid Internet analyst to hold a luncheon meeting »

SMID Internet Analyst…

GRUB

GrubHub

$71.04

-0.13 (-0.18%)

YELP

Yelp

$32.80

-0.13 (-0.39%)

BWLD

Taken private 2/18

$0.00

(0.00%)

CAKE

Cheesecake Factory

$44.35

-1.2 (-2.63%)

BJRI

BJ's Restaurants

$41.00

-1.6 (-3.76%)

CMG

Chipotle

$731.31

-1.41 (-0.19%)

JACK

Jack in the Box

$84.75

-1.61 (-1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 23

    Jul

  • 08

    Aug

14:35
06/19/19
06/19
14:35
06/19/19
14:35
General news
FOMC forecast Revisions »

FOMC forecast Revisions…

SPY

SPDR S&P 500 ETF Trust

$293.00

0.67 (0.23%)

, SPX

S&P 500

$0.00

(0.00%)

14:33
06/19/19
06/19
14:33
06/19/19
14:33
General news
Powell says Fed made 'significant' changes to policy statement »

Fed Chair Jerome Powell…

SPY

SPDR S&P 500 ETF Trust

$293.00

0.67 (0.23%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGN

Inogen

$70.97

-0.13 (-0.18%)

14:32
06/19/19
06/19
14:32
06/19/19
14:32
Conference/Events
William Blair medical tech analyst to hold a luncheon »

Medical Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 26

    Aug

  • 26

    Aug

BJRI

BJ's Restaurants

$41.14

-1.46 (-3.43%)

, CAKE

Cheesecake Factory

$44.50

-1.05 (-2.31%)

14:29
06/19/19
06/19
14:29
06/19/19
14:29
Conference/Events
Wedbush restaurants analyst to hold an analyst/industry conference call »

Restaurants Analyst…

BJRI

BJ's Restaurants

$41.14

-1.46 (-3.43%)

CAKE

Cheesecake Factory

$44.50

-1.05 (-2.31%)

CMG

Chipotle

$729.53

-3.19 (-0.44%)

DIN

Dine Brands

$95.61

-0.39 (-0.41%)

DRI

Darden

$117.36

-0.58 (-0.49%)

JACK

Jack in the Box

$84.90

-1.46 (-1.69%)

SBUX

Starbucks

$83.34

0.39 (0.47%)

TXRH

Texas Roadhouse

$52.30

-1.07 (-2.00%)

WEN

Wendy's

$19.44

0.03 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 23

    Jul

  • 08

    Aug

  • 14

    Aug

  • 27

    Aug

  • 28

    Aug

  • 13

    Nov

14:27
06/19/19
06/19
14:27
06/19/19
14:27
Conference/Events
William Blair financial services/insurance analyst to hold a luncheon »

Financial…

CTSH

Cognizant

$63.45

-0.27 (-0.42%)

14:25
06/19/19
06/19
14:25
06/19/19
14:25
Options
Cognizant call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

14:25
06/19/19
06/19
14:25
06/19/19
14:25
General news
More from the FOMC: a couple of other tweaks the statement »

More from the FOMC: a…

14:24
06/19/19
06/19
14:24
06/19/19
14:24
Conference/Events
CLSA Asian tech analysts to hold an analyst/industry conference call »

Asian Technology Analysts…

UNH

UnitedHealth

$250.20

4.55 (1.85%)

, DVA

DaVita

$51.25

1.49 (2.99%)

14:23
06/19/19
06/19
14:23
06/19/19
14:23
Periodicals
Breaking Periodicals news story on UnitedHealth, DaVita »

FTC set to approve sale…

UNH

UnitedHealth

$250.20

4.55 (1.85%)

DVA

DaVita

$51.25

1.49 (2.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

TSLA

Tesla

$227.28

2.6 (1.16%)

14:22
06/19/19
06/19
14:22
06/19/19
14:22
Hot Stocks
Tesla CEO says $1,000 charge for black vehicles to start next month »

Elon Musk, CEO of Tesla,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,105.94

1.54 (0.14%)

, GOOGL

Alphabet Class A

$1,107.59

2.37 (0.21%)

14:21
06/19/19
06/19
14:21
06/19/19
14:21
Periodicals
FTC in late stages of YouTube probe over children content, Washington Post says »

The Federal Trade…

GOOG

Alphabet

$1,105.94

1.54 (0.14%)

GOOGL

Alphabet Class A

$1,107.59

2.37 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 09

    Jul

  • 10

    Jul

  • 27

    Oct

SYNL

Synalloy

$16.52

-0.27 (-1.61%)

14:21
06/19/19
06/19
14:21
06/19/19
14:21
Earnings
Synalloy lowers FY19 revenue view to $329M from prior $340M »

Adjusted EBITDA for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$55.26

0.6 (1.10%)

14:20
06/19/19
06/19
14:20
06/19/19
14:20
Conference/Events
CVS Health participates in a conference call with Morgan Stanley »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

14:20
06/19/19
06/19
14:20
06/19/19
14:20
General news
FX Action: The dollar »

FX Action: The dollar…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.